Evidence map›Paper›PMID 22315263›Full record

GuidelineChest2012

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Michael K Gould, David A Garcia, Sherry M Wren, Paul J Karanicolas, Juan I Arcelus, John A Heit, Charles M Samama

Erratum issued 4 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
In one paragraph

Guideline in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 703 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
703citing papers in PubMed, 10 pooled it
90.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02597218 unknown statusnot on this mapstarted 2015, after this paper: background citation

Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.

TypeobservationalSponsorHospital Italiano de Buenos AiresRan2015 to 2020Enrolled350ConditionsPulmonary Embolism, Venous Thrombosis, Portal Thrombosis
NCT03070834 nacompletednot on this mapstarted 2017, after this paper: background citation

Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2017 to 2020Enrolled42ConditionsPulmonary Embolism, Trauma, Venous ThromboembolismArmsCook 'Celect' retrievable inferior vena cava filter
NCT06795698 phase2completednot on this mapstarted 2019, after this paper: background citation

The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. a Phase 2, Randomized, Doble Blind, Control Trial

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2019 to 2024Enrolled61ConditionsFractures, Bone, CKD Stage 4, CKD Stage 3, CKD Stage 5ArmsEnoxaparin
NCT06873321 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Incidence of Venous Thromboembolism After Lower Limb Revascularization in Patients Receiving Rivaroxaban 2.5 Mg Bid + Aspirin 100 Mg Versus Single Antiplatelet Treatment - a Randomized Clinical Trial

TypeinterventionalSponsorScience Valley Research InstituteRan2024 to 2025Enrolled100ConditionsPeripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases, Vascular Surgery Patient with PAD / Carotid StenosisArmsrivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
3 · Its place in the literature

Who cites it

703 citing papers in PubMed, 10 syntheses or guidelines pooled it, 2,091 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

643 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 4 countries.

Michael K GouldKeck School of Medicine, University of Southern California, Los Angeles, CA. Electronic address: michael.k.gould@kp.org.
David A GarciaUniversity of New Mexico School of Medicine, Albuquerque, NM.
Sherry M WrenStanford School of Medicine, Stanford, CA.
Paul J KaranicolasSurgical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Juan I ArcelusUniversity of Granada Medical School, Granada, Spain.
John A HeitCollege of Medicine, Mayo Clinic, Rochester, MN.
Charles M SamamaDepartment of Anaesthesiology and Intensive Care, Hotel-Dieu University Hospital, Paris, France.
Health Sciences Centre · CAHôtel-Dieu de Paris · FRMayo Clinic · USStanford Medicine · USUniversidad de Granada · ESUniversity of New Mexico · USUniversity of Southern California · US

Funding

Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based ClinicalR13HL104758 · NHLBI · AMERICAN COLLEGE OF CHEST PHYSICIANS · PI LEWIS, SANDRA ZELMAN · 2010 to 2010
$11k
NHLBI NIH HHS R13 HL104758
6 · The paper itself

Abstract

backgroundVTE is a common cause of preventable death in surgical patients.

methodsWe developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by using systematic methods as described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.

resultsWe describe several alternatives for stratifying the risk of VTE in general and abdominal-pelvic surgical patients. When the risk for VTE is very low (< 0.5%), we recommend that no specific pharmacologic (Grade 1B) or mechanical (Grade 2C) prophylaxis be used other than early ambulation. For patients at low risk for VTE (∼1.5%), we suggest mechanical prophylaxis, preferably with intermittent pneumatic compression (IPC), over no prophylaxis (Grade 2C). For patients at moderate risk for VTE (∼3%) who are not at high risk for major bleeding complications, we suggest low-molecular-weight heparin (LMWH) (Grade 2B), low-dose unfractionated heparin (Grade 2B), or mechanical prophylaxis with IPC (Grade 2C) over no prophylaxis. For patients at high risk for VTE (∼6%) who are not at high risk for major bleeding complications, we recommend pharmacologic prophylaxis with LMWH (Grade 1B) or low-dose unfractionated heparin (Grade 1B) over no prophylaxis. In these patients, we suggest adding mechanical prophylaxis with elastic stockings or IPC to pharmacologic prophylaxis (Grade 2C). For patients at high risk for VTE undergoing abdominal or pelvic surgery for cancer, we recommend extended-duration, postoperative, pharmacologic prophylaxis (4 weeks) with LMWH over limited-duration prophylaxis (Grade 1B). For patients at moderate to high risk for VTE who are at high risk for major bleeding complications or those in whom the consequences of bleeding are believed to be particularly severe, we suggest use of mechanical prophylaxis, preferably with IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C). For patients in all risk groups, we suggest that an inferior vena cava filter not be used for primary VTE prevention (Grade 2C) and that surveillance with venous compression ultrasonography should not be performed (Grade 2C). We developed similar recommendations for other nonorthopedic surgical populations.

conclusionsOptimal thromboprophylaxis in nonorthopedic surgical patients will consider the risks of VTE and bleeding complications as well as the values and preferences of individual patients.

Indexed as

Evidence-Based MedicineSocieties, MedicalSurgical Procedures, OperativeCombined Modality TherapyFibrinolytic AgentsHemorrhageHeparinHeparin, Low-Molecular-WeightIntermittent Pneumatic Compression DevicesPostoperative ComplicationsPulmonary EmbolismRisk FactorsStockings, CompressionUnited StatesVenous ThromboembolismFibrinolytic AgentsHeparinHeparin, Low-Molecular-Weight

Identifiers

PMID22315263
PMCPMC3278061
OpenAlexW2142092434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.